First-in-Human, single-dose, crossover, Phase I safety, tolerability, and pharmacokinetic study of AV104 buccal film and tablet
Latest Information Update: 17 Mar 2021
At a glance
- Drugs Nalmefene (Primary)
- Indications Pruritus
- Focus Adverse reactions; First in man; Pharmacokinetics
- Sponsors Avior Bio
Most Recent Events
- 08 Mar 2021 According to an Avior Bio media release, the company plans to complete this and another pharmacokinetic study in subjects with mild to moderate chronic liver disease. Completion of these studies will unable to finalize the design of phase II program in the treatment of chronic liver disease associated pruritus.
- 24 Jul 2020 New trial record
- 23 Jul 2020 According to an Avior Bio media release, the company will initiate first dose on Friday, July 24, 2020.